risks of glp-1 drugs Use, Risks, and Regulation Know more :https://pib.gov.in/PressReleasePage.aspx?PRID=2247459 Glucagon-like Receptor-1 agonists for obesity:

Glucagon-like peptide 1 (GLP-1) agonists including brand names like Ozempic and Wegovy were created to help people with type 2 diabetes make more insulin and lower their blood sugar

Measuring the correct dose is easy, but so is overmeasuring

A January study published in JAMA Network Open that included 125,474 patients on the medications found that 46.5% of those with type 2 diabetes and 64.8% of those without stopped taking the drugs within one year

doi: 10.3390/medicina59081459, 7

For best results, pair disciplined budgeting with progressive learning: take notes, screenshot unusual boards, and revisit your strategy weekly

By enhancing autophagy and stabilizing mitochondria indirectly via AMPK and SIRT, GLP-1RAs may also act as indirect suppressors of pathological STING activation